Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 13/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25982180 | 0.90 | NAMPT (0.59) | NAMPTADORA1ADORA2ANPC1RAB9A | |
| SCHEMBL25982124 | 0.89 | NAMPT (0.60) | NAMPTADORA1ADORA2ANPC1RAB9A | |
| SCHEMBL17941947 | 0.89 | NAMPT (0.53) | NAMPT | |
| SCHEMBL17941967 | 0.89 | NAMPT (0.62) | NAMPT | |
| SCHEMBL29893059 | 0.86 | NAMPT (0.51) | NAMPT | |
| SCHEMBL25981084 | 0.86 | SMN1; SMN2 (0.67) | ADORA1NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL25982238 | 0.84 | NAMPT (0.54) | NAMPTADORA1ADORA2ANPC1RAB9A | |
| SCHEMBL31529344 | 0.82 | LMNA (0.69) | ADORA1ADORA2ANPC1RAB9AKDM4E | |
| SCHEMBL17941879 | 0.81 | TSHR (0.50) | NAMPTNPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL25982240 | 0.80 | NAMPT (0.51) | NAMPTADORA1ADORA2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145599-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | MRJA THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| CN-118974019-A | Certain chemical entities, compositions and methods | 瑞图恩制药公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2023150663-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | RETUNE PHARMA INC. (US) | 2023-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145599-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | IGF1R, IGFBP1, IGFBP2 | NAMPT 1318/4885ADORA1 2690/4885ADORA2A 1695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.